Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells.

ABSTRACT:

Background

Liquid biopsy, in the form of cell-free-DNA (cfDNA), circulating-tumour-DNA (ctDNA), and circulating tumour cells (CTCs) can be used to monitor the efficacy of systemic therapy. We investigated the predictive value of these markers in patients with advanced non-small cell lung cancer (aNSCLC) treated with pembrolizumab within a prospective phase-II maintenance study of pembrolizumab post-platinum-doublet-chemotherapy (NCT02705820).

Methods

Plasma-derived cfDNA was evaluated in 125 patients' plasma samples at baseline (t0), after 3 weeks (t1), 6 weeks (t2) and 9 weeks (t3) from 46 individuals and analysed by next-generation sequencing to identify and quantify somatic mutations. CTCs were detected in peripheral blood mononuclear cells and characterised according to

SUBMITTER: Kakouri AC 

PROVIDER: S-EPMC12261352 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature